Login
$MASS
$9.19 -$0.55 (5.65%) Live

$MASS 8-K SEC Filings

Filed On Filing
10 Nov 2026 8-K: Results of Operations and Financial Condition

BURLINGTON, Mass. – November 10, 2026 – 908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety, and defense tech applications, today reported fi...

11 Aug 2026 8-K: Results of Operations and Financial Condition

Updated full year 2026 outlook reflects 21% to 25% year-over-year growth

08 Jul 2026 8-K: Other Events

On July 8, 2026, 908 Devices Inc. (the “Company”) issued an aggregate of 3,213,583 shares of the Company’s common stock, par value $0.001 per share (“Common Stock”), in satisfaction of its obligations with respect to the Earnout Consider...

12 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders

On June 11, 2026, 908 Devices Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”). As of April 16, 2026, the record date for the 2026 Annual Meeting, there were 37,446,534 shares of the Company’s...

06 May 2026 8-K: Entry into a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets +3 more

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE 908 DEVICES INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO 908 DEVICES INC. I...

03 Mar 2026 8-K: Results of Operations and Financial Condition

Fourth quarter 2025 revenue increased 21% compared to prior year

20 Jan 2026 8-K: Results of Operations and Financial Condition

Preliminary full year 2025 revenue of approximately $56 million, representing ~17% growth year-over-year

10 Nov 2025 8-K: Results of Operations and Financial Condition

Year-to-date revenue increased 16% while Adjusted EBITDA loss improves 53% quarter over quarter

05 Aug 2025 8-K: Results of Operations and Financial Condition

Revenue from continuing operations grew 14% compared to prior year

04 Aug 2025 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

908 Devices Appoints Dr. Brandi Vann, former U.S. Principal Deputy Assistant Secretary for Nuclear, Chemical, and Biological Defense, to its Board of Directors

16 Jun 2025 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

BOSTON, June 16, 2025 – 908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld devices for chemical analysis, announces that it has appointed Christopher D. Brown, PhD, Vice President, Analytics R&D at Repligen Corporation ...

13 Jun 2025 8-K: Submission of Matters to a Vote of Security Holders

On June 12, 2025, 908 Devices Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “2025 Annual Meeting”). As of April 17, 2025, the record date for the 2025 Annual Meeting, there were 35,739,753 shares of the Company’s...

13 May 2025 8-K: Results of Operations and Financial Condition

Revenue from continuing operations grew 59% compared to prior year, driven by an increase in product and service revenue

04 Mar 2025 8-K: Results of Operations and Financial Condition

Divested desktop portfolio to Repligen for $70 million, including the MAVEN, MAVERICK, REBEL and ZipChip products

04 Mar 2025 8-K: Entry into a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets +1 more

EXHIBIT C – Bill of Sale and Assignment and Assumption Agreement

12 Nov 2024 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Revenue increases 17% compared to prior year, driven by recently acquired handheld products

30 Aug 2024 8-K: Regulation FD Disclosure

On August 30, 2024, 908 Devices Inc. (“908 Devices”) posted an updated Investor Presentation on its investor relations website at ir.908devices.com. Members of 908 Devices’ management will use the presentation in connection with meetings...

06 Aug 2024 8-K: Results of Operations and Financial Condition

Revenue increases 16% compared to prior year, driven by newly acquired handheld products

25 Jun 2024 8-K: Departure/Election of Directors or Officers; Compensation

908 Devices Appoints Michele M. Leonhart, Former Administrator of the United States Drug Enforcement Administration (DEA), to its Board of Directors

14 Jun 2024 8-K: Submission of Matters to a Vote of Security Holders

On June 13, 2024, 908 Devices Inc. (the “Company”) held its 2024 Annual Meeting of Stockholders (the “2024 Annual Meeting”). As of April 19, 2024, the record date for the 2024 Annual Meeting, there were 32,983,276 shares of the Company’s...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support